Price
No data yet.
Social Signal Score
Analyst Ratings
38 analystsRevenue
$2.94B+22.39%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Thomas J. Appio
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 20,300
- Beta
- 0.37
- Country
- CA
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 0.22
Financials
Revenue
$2.94B+22.4%Net Income
$436.00MEBITDA
$1.28B+27.1%Free Cash Flow
$748.00M+66.0%EPS (diluted)
$1.15Shares Outstanding (diluted)
380.70M+8.9%Operating Expenses
$975.00MCash & Debt
$2.48BReturn of Capital
$0.00Revenue by Segment (annual)
$20.53BDividend per Share
$1.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.27B | $157.00M | $0.43 |
| 2024 | $9.63B | $-46.00M | $-0.13 |
| 2023 | $8.76B | $-592.00M | $-1.62 |
| 2022 | $8.12B | $-225.00M | $-0.62 |
| 2021 | $8.43B | $-948.00M | $-2.61 |
| 2020 | $8.03B | $-559.00M | $-1.57 |
| 2019 | $8.60B | $-1.78B | $-5.06 |
| 2018 | $8.38B | $-4.15B | $-11.86 |
| 2017 | $8.72B | $2.40B | $8.63 |
| 2016 | $9.67B | $-2.41B | $-6.94 |
| 2015 | $10.44B | $-268.66M | $-0.78 |
| 2014 | $8.20B | $881.00M | $3.16 |
| 2013 | $5.77B | $-866.14M | $-2.70 |
| 2012 | $3.48B | $-116.03M | $-0.38 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.62
- Implied price
- $9.95
- Return from $8.22
- 3.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.95 — -39.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -2.0% | -11.0% | -8.2% | -5.7% | -3.5% | -1.4% |
| 3.0% | -6.5% | -3.5% | -0.9% | 1.4% | 3.6% |
| 8.0% | -1.9% | 1.2% | 3.9% | 6.4% | 8.6% |
| 13.0% | 2.6% | 5.8% | 8.7% | 11.3% | 13.7% |
| 18.0% | 7.2% | 10.5% | 13.5% | 16.2% | 18.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (18)
- Newsprnewswire.com·3d ago·Neutral
…des of innovation and continued global adoption of Solta Medical's aesthetic technologies LAVAL, QC, Nov. 20, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, today announced that Solta Medical has surpassed 10 million treatments worldwide across its aesthetic technology portfolio, marking a significant milestone in the company's history. As the manufacturer of…
View source ↗ - Newsprnewswire.com·16d ago·Neutral
…ta on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 LAVAL, QC, Nov. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, will present a research poster at the American Association for the Study of Liver Diseases' The Liver Meeting® 2026, November 5–9 in Denver, Colorado. The study highlights the substantial mortality and rehospitalization among patients hospitalized with sev…
View source ↗ - Newszacks.com·24d ago·Positive
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Bausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript Bausch Health Companies Inc. ( BHC ) Q3 2026 Earnings Call October 28, 2026 5:00 PM EDT Company Participants Garen Sarafian Thomas Appio - CEO & Director Jean-Jacques Charhon - Executive VP & CFO Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Greetings, and welcome to the Bausch Health Third Quarter 202…
View source ↗ - Newszacks.com·25d ago·Neutral
Bausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·25d ago·Positive
Bausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates Bausch Health (BHC) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.16 per share a year ago.
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call Bausch Health Cos NYSE: BHC raised its full-year 2026 outlook for the second consecutive quarter after reporting third-quarter growth across its operating segments, led by Salix and supported by international operations and Solta Medical.
View source ↗ - Newszacks.com·27d ago·Neutral
BHC Q3 Earnings Preview: Here's What You Should Know Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.
View source ↗ - Newsprnewswire.com·41d ago·Positive
…d Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway LAVAL, QC, Oct. 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management demonstrated improved adherence to evidence-based monitoring and treatment practices across community gastroenterology settings. T…
View source ↗ - Newsbusinesswire.com·41d ago·Neutral
…io--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir.
View source ↗ - Newsprnewswire.com·47d ago·Neutral
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026 LAVAL, QC, Oct. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2026 financial results after market close on Wednesday, October 28, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m.
View source ↗ - Newszacks.com·53d ago·Neutral
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks BHC, CDNA, DOLE and CHEF offer defensive exposure as consumer confidence falls amid inflation and geopolitical tensions.
View source ↗ - Newszacks.com·61d ago·Positive
Best Value Stocks to Buy for September 22nd BHC, OPHC and TRVG made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 22nd, 2026.
View source ↗ - Newszacks.com·93d ago·Neutral
Can Bausch (BHC) Run Higher on Rising Earnings Estimates? Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newszacks.com·93d ago·Positive
Bausch (BHC) Upgraded to Buy: Here's What You Should Know Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·94d ago·Positive
Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and
View source ↗ - Newsseekingalpha.com·102d ago·Neutral
Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, but balance sheet risks remain paramount. BHC delivered Q2 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and notable margin and cash flow improvements. Despite operational momentum, BHC's $15B long-term debt and $800M H1 interest expense drive speculative credit ratings and analyst skepticism.
View source ↗ - Newszacks.com·103d ago·Positive
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗
Earnings
Wed, Feb 17(in 3 months)
Consensus estimate $1.35 per share
Typical surprise -3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 28$1.77 vs $1.25beat
- Wed, Jul 29$1.26 vs $0.96beat
- Wed, Apr 29$0.78 vs $0.81miss
- Wed, Feb 18$1.08 vs $1.21miss
- Wed, Oct 29$1.16 vs $1.07beat
- Wed, Jul 30$0.90 vs $0.97miss
Estimates and results for BHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BHC officers and directors.
- Bought
- $385.3m
- Sold
- $726k
9 trades
7 trades
- Lenar Aimee J.sold
- Lee Frank D.sold
- Carson Seanasold
- Carson Seanasold
- Carson Seanasold
- Paulson & Co. Inc.bought
- Carson Seanasold
- Lee Frank D.sold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Susie Leehouse · NV03 · disclosed Oct 7, 2020 (41d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Apr 28, 2020 (64d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Feb 25, 2020 (50d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
